Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Acquisitions (2021 - 2023)

Oncology Institute (TOI) has disclosed Acquisitions for 3 consecutive years, with $156000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Acquisitions fell 66.81% year-over-year to $156000.0, compared with a TTM value of $156000.0 through Dec 2024, up 183.42%, and an annual FY2023 reading of $4.5 million, down 48.05% over the prior year.
  • Acquisitions was $156000.0 for Q4 2023 at Oncology Institute, down from $470000.0 in the prior quarter.
  • Across five years, Acquisitions topped out at $8.9 million in Q2 2022 and bottomed at -$813000.0 in Q3 2022.
  • Average Acquisitions over 3 years is $3.0 million, with a median of $648500.0 recorded in 2021.
  • The sharpest move saw Acquisitions tumbled 94.32% in 2022, then plummeted 66.81% in 2023.
  • Year by year, Acquisitions stood at $8.3 million in 2021, then crashed by 94.32% to $470000.0 in 2022, then tumbled by 66.81% to $156000.0 in 2023.
  • Business Quant data shows Acquisitions for TOI at $156000.0 in Q4 2023, $470000.0 in Q4 2022, and -$813000.0 in Q3 2022.